Patents by Inventor Marcello A. Giulianotti

Marcello A. Giulianotti has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11932628
    Abstract: The invention provides compounds having the general formula I: and salts thereof, wherein the variables R1, R2, R3 and R4 have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Grant
    Filed: January 3, 2022
    Date of Patent: March 19, 2024
    Assignee: REGENTS OF THE UNIVERSITY OF MINNESOTA
    Inventors: Carrie Haskell-Luevano, Skye Ross Doering, Marcello A. Giulianotti, Clemencia Pinilla, Radleigh G. Santos, Richard A. Houghten
  • Publication number: 20230219942
    Abstract: The present disclosure relates to compounds of Formula (I): (I), wherein R1, R2, L1, L2, Y1, Y2, Y3, X1, Ring A, Ring B and Ring C are as defined herein, as well as to compositions comprising such compounds. The compounds and compositions may be useful for treating diseases and conditions that are amenable to treatment by blocking PD-1, PD-L1 and/or the PD-1/PD-L1 interaction, cancers, sepsis and/or autoimmune diseases.
    Type: Application
    Filed: June 2, 2021
    Publication date: July 13, 2023
    Inventors: George L. Trainor, Perry Molinoff, Adel Nefzi, Marcello Giulianotti, Richard Houghten
  • Publication number: 20230135119
    Abstract: The present disclosure relates to methods of using palmitoylation inhibitors for reducing or treating enveloped virus infections.
    Type: Application
    Filed: October 6, 2022
    Publication date: May 4, 2023
    Inventors: Robert Deschenes, Arunava Roy, Ahmed Ramadan, Subhra Mohapatra, Marcello Giulianotti
  • Publication number: 20230099379
    Abstract: Disclosed herein are compounds, compositions, and methods for selecting targeting ?2AR receptors. The compounds, compositions, and methods may be used in the treatment of obstructive lung diseases.
    Type: Application
    Filed: September 2, 2022
    Publication date: March 30, 2023
    Inventors: Stephen Bryant Liggett, Donghwa Kim, Marcello Giulianotti
  • Publication number: 20220213068
    Abstract: The invention provides compounds having the general formula I: and salts thereof, wherein the variables R1, R2, R3 and R4 have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Application
    Filed: January 3, 2022
    Publication date: July 7, 2022
    Inventors: Carrie Haskell-Luevano, Skye Ross Doering, Marcello A. Giulianotti, Clemencia Pinilla, Radleigh G. Santos, Richard A. Houghten
  • Patent number: 11149028
    Abstract: The invention provides methods for treating cancers, such as melanoma and/or metastatic melanoma, using compounds that interact with and/or inhibit cellular proteins lamin A/C, ATP-dependent RNA helicase DDX1 (DDX1), heterogeneous nuclear ribonuclear protein H1/H2 (hnRNP H2), and/or heterogeneous nuclear ribonuclear protein A2/B1 (hnRNP A2/B1). The invention additionally provides a method for identifying compounds active against melanoma cells.
    Type: Grant
    Filed: December 15, 2017
    Date of Patent: October 19, 2021
    Assignees: Nova Southeastern University, Auburn University, Florida Atantic University Board Of Trustees, Torrey Pines Institute for Molecular Studies
    Inventors: Dmitriy Minond, Gregg B. Fields, Marcello Giulianotti
  • Patent number: 11014876
    Abstract: Cancer is a disease for which there remains a great unmet medical need, and therefore the discovery and development of new antineoplastic agents is critically important. The present invention relates in part to new therapeutic compounds with antineoplastic activity. Provided herein are polyamine sulfonamides such as compounds of Formula (I), or pharmaceutically acceptable salts thereof, which may be used in the treatment and/or prevention of diseases such as cancer. Also provided herein are pharmaceutical compositions and kits comprising the inventive compounds. Furthermore, the present invention provides methods of treating and/or preventing diseases (e.g., cancer) using compounds of Formula (I), or pharmaceutically acceptable salts thereof or pharmaceutical compositions thereof. Other methods provided include methods for inducing apoptosis of a cell, as well as methods for inhibiting alpha-enolase enzymatic activity in vivo and in vitro.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: May 25, 2021
    Assignees: University of Florida Research Foundation, Inc., Torrey Pines Institute for Molecular Studies
    Inventors: Christopher R. Cogle, Amy M. Meacham, Peter P. Sayeski, Marcello A. Giulianotti, Richard A. Houghten, Gregory S. Welmaker
  • Publication number: 20200179361
    Abstract: The present disclosure provides compositions including a ?4?2 nAChR antagonist, pharmaceutical compositions including a ?4?2 nAChR antagonist, methods of making the compositions or pharmaceutical compositions, methods of treatment of a condition (e.g., nicotine addiction) or disease, methods of treatment using compositions or pharmaceutical compositions, and the like. Embodiments of the present disclosure can be used to reduce nicotine cravings and treat nicotine addiction. The compositions have selective affinity for the ?4?2 receptor, which appears to be involved in nicotine dependence.
    Type: Application
    Filed: May 21, 2018
    Publication date: June 11, 2020
    Inventors: Marcello GIULIANOTTI, Lawrence TOLL, Gregory S. WELMAKER, Jinhua WU, Yongping YU
  • Publication number: 20200062736
    Abstract: The invention provides methods for treating cancers, such as melanoma and/or metastatic melanoma, using compounds that interact with and/or inhibit cellular proteins lamin A/C, ATP-dependent RNA helicase DDX1 (DDX1), heterogeneous nuclear ribonuclear protein H1/H2 (hnRNP H2), and/or heterogeneous nuclear ribonuclear protein A2/B1 (hnRNP A2/B1). The invention additionally provides a method for identifying compounds active against melanoma cells.
    Type: Application
    Filed: December 15, 2017
    Publication date: February 27, 2020
    Applicants: NOVA SOUTHEASTERN UNIVERSITY, AUBURN UNIVERSITY, FLORIDA ATLANTIC UNIVERSITY BOARD OF TRUSTEES, TORREY PINES INSTITUTE FOR MOLECULAR STUDIES
    Inventors: Dmitriy Minond, Gregg B. Fields, Marcello Giulianotti
  • Publication number: 20180297942
    Abstract: Cancer is a disease for which there remains a great unmet medical need, and therefore the discovery and development of new antineoplastic agents is critically important. The present invention relates in part to new therapeutic compounds with antineoplastic activity. Provided herein are polyamine sulfonamides such as compounds of Formula (I), or pharmaceutically acceptable salts thereof, which may be used in the treatment and/or prevention of diseases such as cancer. Also provided herein are pharmaceutical compositions and kits comprising the inventive compounds. Furthermore, the present invention provides methods of treating and/or preventing diseases (e.g., cancer) using compounds of Formula (I), or pharmaceutically acceptable salts thereof or pharmaceutical compositions thereof. Other methods provided include methods for inducing apoptosis of a cell, as well as methods for inhibiting alpha-enolase enzymatic activity in vivo and in vitro.
    Type: Application
    Filed: November 4, 2016
    Publication date: October 18, 2018
    Applicants: University of Florida Research Foundation, Inc., Torrey Pines Institute for Molecular Studies
    Inventors: Christopher R. Cogle, Amy M. Meacham, Peter P. Sayeski, Marcello A. Giulianotti, Richard A. Houghten, Gregory S. Welmaker